Response Genetics Inc. announced it has launched a new and innovative Non-Small Cell Lung Cancer Profile that merges rapid turnaround on National Comprehensive Cancer Network (NCCN) guideline markers with next-generation sequencing (NGS). This new reflex, or sequential, testing program offers oncologists and pathologists a cost-effective way to utilize comprehensive cancer testing, including NGS, as a reflex-testing option for those patients who test negative for EGFR, ALK and ROS1, the biomarkers recommended by the NCCN.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% |
|
-.--% | -.--% |
2016 | Response Genetics, Inc Bankruptcy Case Dismissed | CI |
2016 | Motion for Case Dismissal Filed for Response Genetics, Inc | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 38 | |
+23.50% | 45.01B | |
+47.19% | 40.96B | |
-5.16% | 38.62B | |
+36.37% | 32.6B | |
-7.79% | 27.49B | |
+18.06% | 27.17B | |
+47.29% | 14.61B | |
+41.91% | 12.95B | |
-1.02% | 11.36B |
- Stock Market
- Equities
- RGDXQ Stock
- News Response Genetics, Inc
- Response Genetics, Inc. Launches New and Innovative Non-Small Cell Lung Cancer Profile